CarlaIFalksonMD

Oncology • Rochester, NY

Breast Cancer

Professor of Medicine and Oncology, University of Rochester New York

Join to view full profile

Dr. Falkson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Falkson's full profile

Already have an account?

Office
125 Red Creek Dr
Rochester, NY 14623
Phone+1 585-486-0600

Fax+1 585-486-0649

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 1986 - 1987
University of Pretoria Faculty of MedicineClass of 1982

Certifications & Licensure

NY State Medical License 2019 - 2025
AL State Medical License 2000 - 2019

Awards, Honors, & Recognition

Unsung Hero Award Division of hematology Oncology Dept Medicine UAB, 2018
Regional Top Doctor Castle Connolly, 2014
Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012

Clinical Trials

S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer. Start of enrollment: 2005 Jul 01
Completed
Phase 3
Study of Avastin (Bevacizumab) to Reverse Acquired Estrogen Independence in Previously Hormone Responsive Metastatic Breast Ca. Start of enrollment: 2005 Oct 01
Completed
Phase 2
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2013 Jan 18
Active, not recruiting
Phase 2
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

6 citations
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.
Rebecca A Shatsky, Meghna S Trivedi, Christina Yau, Rita Nanda, Hope S Rugo
Nature Medicine. 2024-12-01
3 citations
Oral SERD, a Novel Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer.
Niraj Neupane, Sawyer Bawek, Sayuri Gurusinghe, Elham Moases Ghaffary, Omid Mirmosayyeb
Cancers. 2024-01-31
A Pilot Study of the Combination of Entinostat with Capecitabine in Advanced Breast Cancer.
Trish Millard, Christiana Brenin, Clare Humphrey, Ajay Dhakal, Carla Falkson
International Journal of Breast Cancer. 2024-01-01

Journal Articles

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast Cancer
Rita Nanda, Carla Falkson, Filipa C Lynce, Claudine Isaacs, Marcelo Blaya, Elisavet Paplomata, Radhika Walling, Reshma Mahtani, Tarah J Ballinger, Kathy D Miller, Brya..., JAMA Oncology

Authored Content

Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy with Disease Recurrence in Patients with Triple-Negative Breast CancerJuly 2020

Press Mentions

Breast Cancer and the COVID Vaccine: What You Need to KnowMarch 1st, 2021
Guided by Research, Wilmot’s Breast Cancer Program Comes of AgeOctober 19th, 2023